Compare Devon Energy Corp (DVN) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Heron Therapeutics Inc — how do they compare? Devon Energy Corp trades at $48.84 (market cap $53.81B), while Heron Therapeutics Inc trades at $0.37 (market cap $68.01M). The key difference: Devon Energy Corp is far larger — about 791.2× Heron Therapeutics Inc's market cap, and Devon Energy Corp pays a 2.62% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Heron Therapeutics Inc for 35 Days on average.
| DVN | HRTX | |
|---|---|---|
Market Cap | $53.81B | $68.01M |
Volume | 11,556,740 | 1,891,941 |
Sector | Energy | Health |
52-Week High | $52.07 | $1.49 |
52-Week Low | $31.74 | $0.27 |
Typical Hold Time | 136 Days | 35 Days |
Enterprise Value | $64.55B | $174.75M |
Dividend Yield | 2.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $47.88, down 0.29% with a bullish technical signal from moving averages. The company shows solid fundamentals with a P/E of 10.41 and net margin of 16.67%, though revenue declined from $19.2B in 2022 to $17.2B in 2025. Recent news highlights activist investor pressure for strategic alternatives and potential asset sales, while analyst consensus remains strongly bullish with a $62.40 price target representing 30% upside.
DVN presents a compelling value opportunity with attractive valuation metrics and strong cash flow generation. However, investors face risks from oil price volatility, execution challenges in asset sales, and competitive pressures in the shale sector. The company's Permian Basin focus and potential strategic moves provide catalysts, but macroeconomic headwinds could impact near-term performance.
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
